John D. Diekman

John D. Diekman, Ph.D. served as a Managing Partner from 2002 to 2015 and transitioned to Founding Partner in 2016. Prior to founding 5AM in 2002, Dr. Diekman was a Founder and Managing Director of Bay City Capital. Previously Dr. Diekman was Chairman and CEO of Affymetrix, and Chairman and Managing Director of Affymax. He currently serves on the Boards of Wildcat Discovery Technologies and Cleave Therapeutics. Dr. Diekman was formerly Chairman of IDEAYA (IPO) and Ambrx (acquired by a Chinese consortium). He was a Director of Calibrium (acquired by Novo Nordisk), Cellular Research (acquired by Becton Dickinson), Chemdex (IPO), Envoy (acquired by Takeda), Ingenuity (acquired by Qiagen), LJL Bio- Systems (IPO), Marcadia (acquired by Roche) and PhaseRx. He has been a Charter Trustee of Princeton University and a former Trustee of The California Institute of Technology. He is Chairman of The Scripps Research Institute, and a board member of Zai Lab Ltd. He serves on the Advisory Board of the Schaeffer Center for Health Policy and the Economics at the University of Southern California. He is an Honorary Officer of the Order of Australia. Dr. Diekman received a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University. He holds an Honorary Degree of Doctor of Laws from Monash University. Dr. Diekman is based in the San Francisco, CA office.